Israeli Health Tech Startups See 20% Drop in Venture Capital Funding in 2024, Report Shows
Israeli health technology startups received 20% less venture capital funding in 2024 compared to the previous year, according to a report by the Israel Innovation Authority. The decline follows a broader slowdown in global tech investment, exacerbated by geopolitical tensions and shifting investor priorities.
What Caused the Drop in Funding?
The Israel Innovation Authority’s annual report, published in March 2025, noted that health tech startups secured $1.2 billion in 2024, down from $1.5 billion in 2023. The agency attributed the decrease to “increased risk aversion among investors” and “regulatory uncertainties in digital health markets.” A separate analysis by Start-Up Nation Central, a non-profit tracking Israeli innovation, highlighted that global venture capital funding for health tech fell by 25% in 2024, with Israel’s decline mirroring this trend.
“Investors are prioritizing later-stage companies with proven revenue models over early-stage ventures,” said Dr. Rachel Cohen, a venture capitalist specializing in health tech. “This shift has disproportionately affected Israeli startups, which often rely on foreign capital.”
How Does This Compare to Other Sectors?
The decline in health tech funding contrasts with growth in other Israeli tech sectors. Cybersecurity startups, for example, saw a 10% increase in funding in 2024, according to the Israel Trade Ministry. Similarly, AI-driven fintech companies raised 15% more capital, reflecting investor confidence in technologies with clear scalability.
However, health tech faces unique challenges. “Regulatory hurdles, such as FDA approval timelines, create delays that deter investors,” said Dr. Michael Levi, a healthcare policy analyst at Hebrew University. “Additionally, the sector’s reliance on long development cycles makes it less attractive in a market increasingly focused on short-term returns.”
What Are the Implications for Israeli Innovation?
The funding slowdown has raised concerns about Israel’s position as a global tech hub. The country, often called “the Start-Up Nation,” has historically been a leader in health tech, with companies like Medtronic and Teva investing heavily in local innovation. However, the 2024 data suggests a potential slowdown in breakthroughs.
“If this trend continues, Israel could lose its competitive edge in health tech,” said Noa Ben-Yehuda, CEO of HealthTech Israel, a industry group. “But there are also opportunities—many startups are focusing on cost-effective solutions for emerging markets, which could attract new investors.”
What’s Next for Israeli Health Tech?
Industry leaders are pushing for policy changes to stabilize funding. The Israel Innovation Authority has launched a $200 million initiative to support early-stage health tech ventures, while private firms are exploring partnerships with global pharmaceutical companies. Analysts remain divided on whether these measures will reverse the decline.
“The sector has weathered downturns before,” said Dr. Cohen. “But this time, the combination of global economic pressures and regulatory complexity makes the path forward more uncertain.”
As 2025 unfolds, the health tech landscape in Israel will be closely watched by investors and policymakers alike. The coming months may determine whether the country can maintain its reputation as a pioneer in medical innovation.